Controlled-release tablets, method of making, and method of use thereof
Disclosed are gastroretentive, sustained-release tablet formulations comprising an active agent, such as pregabalin or a pharmaceutically acceptable form thereof, crospovidone, and a cationic copolymer based on dimethylaminoethyl methacrylate, butyl methacrylate, and methyl methacrylate random copolymer.
1. A non-effervescent gastroretentive, sustained-release tablet formulation, comprising a tablet matrix comprising:
pregabalin or a pharmaceutically acceptable complex, salt, solvate, hydrate, or polymorph thereof;
crospovidone present in an amount of about 20 to about 40 wt. % of the total weight of the tablet matrix excluding the weight of the pregabalin or a pharmaceutically acceptable complex, salt, solvate, hydrate, or polymorph thereof;
a cationic dimethylaminoethyl methacrylate, butyl methacrylate, and methyl methacrylate random copolymer present in an amount of about 2.5 to about 5.0 wt. % of the total weight of the tablet matrix excluding the weight of the pregabalin or a pharmaceutically acceptable complex, salt, solvate, hydrate, or polymorph thereof; and
a controlled-release polymer which is a hydroxypropyl methyl cellulose present in an amount of about 40 to about 74 wt. % of the total weight of the tablet matrix excluding the weight of the pregabalin or a pharmaceutically acceptable complex, salt, solvate, hydrate, or polymorph thereof.
2. The non-effervescent gastroretentive, sustained-release tablet formulation of claim 1 , wherein
crospovidone is present in an amount of about 24 to about 36 wt. % of the total weight of the tablet matrix excluding the weight of the pregabalin or a pharmaceutically acceptable complex, salt, solvate, hydrate, or polymorph thereof; and
the cationic dimethylaminoethyl methacrylate, butyl methacrylate, and methyl methacrylate random copolymer is present in an amount of about 3.0 to about 4.5 wt. % of the total weight of the tablet matrix excluding the weight of the pregabalin or a pharmaceutically acceptable complex, salt, solvate, hydrate, or polymorph thereof.
3. The non-effervescent gastroretentive, sustained-release tablet formulation of claim 1 , wherein the weight ratio of crospovidone to cationic dimethylaminoethyl methacrylate, butyl methacrylate, and methyl methacrylate random copolymer in the tablet is about 6:1 to about 11:1.
4. The non-effervescent gastroretentive, sustained-release tablet formulation of claim 1 , wherein the pregabalin or a pharmaceutically acceptable complex, salt, solvate, hydrate, or polymorph thereof is present in an amount of about 2.0 to about 50 wt. % of the total weight of the tablet matrix.
5. The non-effervescent gastroretentive, sustained-release tablet formulation of claim 1 , comprising pregabalin present in an amount of about 50 to about 450 mg per tablet.
6. The non-effervescent gastroretentive, sustained-release tablet formulation of claim 1 , comprising pregabalin present in an amount of about 82.5 mg per tablet.
7. The non-effervescent gastroretentive, sustained-release tablet formulation of claim 1 , further comprising a binder, a filler, a disintegrant, a lubricant, a glidant, or a combination thereof.
8. The non-effervescent gastroretentive, sustained-release tablet formulation of claim 1 , wherein the controlled-release polymer is a hydroxypropyl methyl cellulose present in an amount of about 40 to about 69 wt. % of the total weight of the tablet matrix excluding the weight of the pregabalin or a pharmaceutically acceptable complex, salt, solvate, hydrate, or polymorph thereof.
9. The non-effervescent gastroretentive, sustained-release tablet formulation of claim 1 , wherein the controlled-release polymer is a hydroxypropyl methyl cellulose present in an amount of about 45 to about 69 wt. % of the total weight of the tablet matrix excluding the weight of the pregabalin or a pharmaceutically acceptable complex, salt, solvate, hydrate, or polymorph thereof.
10. The non-effervescent gastroretentive, sustained-release tablet formulation of claim 7 , wherein the binder, filler, lubricant, glidant, or any combination thereof is present in an amount of about 0.1 to about 11 wt. % of the total weight of tablet matrix excluding the weight of the pregabalin or a pharmaceutically acceptable complex, salt, solvate, hydrate, or polymorph thereof.
11. The non-effervescent gastroretentive, sustained-release tablet formulation of claim 1 , further comprising an immediate-release coating.
12. A non-effervescent gastroretentive, sustained-release tablet formulation, comprising:
a tablet matrix comprising
about 29 to about 30 wt. % of pregabalin;
about 21 to about 24 wt. % crospovidone;
about 2.5 to about 2.75 wt. % of a cationic dimethylaminoethyl methacrylate, butyl methacrylate, and methyl methacrylate random copolymer;
about 39 to about 41 wt. % hydroxypropyl methyl cellulose; and
the balance is about 4 to about 6 wt. % of binder, filler, lubricant, glidant, or any combination thereof,
wherein all the amounts are based on the total weight of tablet matrix.
13. A non-effervescent gastroretentive, sustained-release tablet formulation, comprising
a tablet matrix comprising
an active agent or a pharmaceutically acceptable complex, salt, solvate, hydrate, or polymorph thereof;
crospovidone in an amount of about 20 to about 40 wt. %;
a cationic dimethylaminoethyl methacrylate, butyl methacrylate, and methyl methacrylate random copolymer in an amount of about 2.5 to about 5.0 wt. %;
hydroxypropyl methyl cellulose controlled-release polymer in an amount of about 40 to about 74 wt. %; and
the balance is binder, filler, lubricant, glidant, or any combination thereof, in an amount of about 0.1 to about 11 wt. %;
wherein the amounts are based on the total weight of the tablet matrix excluding the weight of the active agent.
14. The non-effervescent gastroretentive, sustained-release tablet formulation of claim 13 , wherein the active agent is pregabalin or a pharmaceutically acceptable complex, salt, solvate, hydrate, or polymorph thereof.
15. The non-effervescent gastroretentive, sustained-release tablet formulation of claim 1 , wherein the tablet is free of a controlled-release coating and free of an osmotic coating.
16. A method of making the non-effervescent gastroretentive, sustained-release tablet formulation of claim 1 , comprising
wet granulating pregabalin with a controlled-release polymer, a binder, and a granulation liquid to form wet granulates;
drying the wet granulates to form dried granulates;
blending the dried granulates with crospovidone, a cationic dimethylaminoethyl methacrylate, butyl methacrylate, and methyl methacrylate random copolymer, and optionally a filler, a lubricant, a glidant or a combination thereof, to form a blend; and
compressing the blend into tablets.
17. A method of treating a subject in need thereof, comprising:
administering the non-effervescent gastroretentive, sustained-release tablet formulation of claim 1 to the subject to treat neuropathic pain, epilepsy, fibromyalgia, or generalized anxiety disorder.
18. The method of claim 17 , wherein the gastroretentive, sustained-release pregabalin tablet formulation is administered to the subject once daily.
19. The gastroretentive, sustained-release pregabalin tablet formulation of claim 1 comprising 330 mg pregabalin exhibits a dissolution profile such that after combining the tablet with 900 ml of a pH 4.5 aqueous dissolution medium at 37° C.±0.5° C. according to USP <711> test method 2 (paddle), 50 rpm paddle speed,
about 39 to about 43 wt. % of the total amount of pregabalin is released at 6 hour;
about 59 to about 64 wt. % of the total amount of pregabalin is released at 12 hours;
about 69 to about 74 wt. % of the total amount of pregabalin is released at 16 hours;
about 77 to about 83 wt. % of the total amount of pregabalin is released at 20 hours; and
about 80 to about 90 wt. % of the total amount of pregabalin is released at 24 hours.